Aplastic anemia

What is Aplastic anemia?

Aplastic anemia is a rare and serious blood disorder where the bone marrow fails to produce enough blood cells of all types—red blood cells, white blood cells, and platelets. This condition, also known as bone marrow failure syndrome, can be either acquired through autoimmune processes or inherited through genetic mutations. It affects approximately 2 people per million each year globally, making it one of the rarer hematologic conditions. While the diagnosis can be devastating, advances in treatment have significantly improved outcomes for many patients.

Key statistics

Symptoms

Primary symptoms: Fatigue, frequent infections, easy bruising and bleeding, shortness of breath, pale skin, rapid heart rate.

The symptoms of aplastic anemia develop due to pancytopenia—the deficiency of all blood cell types. Anemia symptoms from low red blood cells include severe fatigue, weakness, shortness of breath during normal activities, dizziness, and pale skin or nail beds. Neutropenia symptoms from low white blood cells lead to frequent, severe, or unusual infections, including bacterial, viral, or fungal infections that may be life-threatening. Thrombocytopenia symptoms from low platelets cause easy bruising, petechiae (small red or purple spots on the skin), frequent nosebleeds, bleeding gums, heavy menstrual periods, and prolonged bleeding from minor cuts. Many patients also experience rapid or irregular heartbeat as the heart works harder to pump oxygen-poor blood throughout the body.

Causes and risk factors

Aplastic anemia has two main categories: acquired and inherited. Acquired aplastic anemia accounts for about 80-90% of cases and is primarily caused by autoimmune destruction of bone marrow stem cells. Environmental triggers may include exposure to certain chemicals (benzene, pesticides), radiation, viral infections (hepatitis viruses, Epstein-Barr virus, parvovirus B19), and medications (chloramphenicol, some chemotherapy drugs, certain antibiotics). Inherited aplastic anemia results from genetic mutations affecting bone marrow function, including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and Diamond-Blackfan anemia. Risk factors include previous cancer treatment, autoimmune disorders, certain viral infections, occupational chemical exposure, and family history of bone marrow failure syndromes. In many cases, particularly in acquired forms, no specific trigger can be identified.

Submit Your Paper

Prevention

For acquired aplastic anemia, prevention focuses on avoiding known environmental triggers when possible, including limiting exposure to industrial chemicals, pesticides, and unnecessary radiation. Healthcare workers should follow safety protocols when handling chemotherapy drugs or other potentially harmful substances. However, many cases occur without identifiable triggers, making prevention challenging. For inherited forms, genetic counseling and testing can help families understand risks and make informed reproductive decisions. Carrier testing is available for known genetic causes like Fanconi anemia, where parents who are both carriers have a 25% chance of having an affected child with each pregnancy. Preimplantation genetic diagnosis may be considered for families with known genetic risks.

Complications

Without treatment, aplastic anemia is often fatal due to severe infections, uncontrolled bleeding, or organ failure from severe anemia. Immediate complications include life-threatening infections due to neutropenia, severe bleeding episodes that can be fatal, and heart failure from severe anemia. Long-term complications may include iron overload from frequent blood transfusions, leading to organ damage in the heart, liver, and endocrine glands. Some patients may develop clonal hematologic disorders, including paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), or acute leukemia years after treatment. Chronic complications from treatment itself can include increased infection risk from immunosuppressive therapy and potential secondary cancers from certain treatments.

Diagnosis

Diagnosis requires a combination of blood tests and bone marrow examination. Complete blood count (CBC) reveals pancytopenia with low levels of all blood cell types. Reticulocyte count is typically low, indicating decreased red blood cell production. Bone marrow biopsy and aspiration are essential, showing hypocellular bone marrow with less than 25% normal cellularity and absence of abnormal cells that might suggest other conditions. Cytogenetic testing helps rule out myelodysplastic syndromes and other clonal disorders. Flow cytometry may detect paroxysmal nocturnal hemoglobinuria clones. Genetic testing should be considered, especially in younger patients or those with family history, to identify inherited bone marrow failure syndromes. Additional tests include vitamin B12 and folate levels, viral serologies, and autoimmune markers to identify potential underlying causes.

Treatment

Treatment depends on disease severity, patient age, and availability of matched donors. Hematopoietic stem cell transplantation is the preferred treatment for younger patients with matched sibling donors, offering the best chance for cure. Immunosuppressive therapy is the standard treatment for patients without suitable donors or older patients, typically combining antithymocyte globulin with ciclosporin. Eltrombopag, a thrombopoietin receptor agonist, has shown promise in stimulating bone marrow recovery and is increasingly used in combination with immunosuppressive therapy. Supportive care includes blood and platelet transfusions, antibiotics for infections, and iron chelation therapy for transfusion-related iron overload. Second-line treatments may include alternative immunosuppressive regimens, alemtuzumab, or haploidentical stem cell transplantation for refractory cases.

Prognosis

Prognosis has improved significantly over recent decades. With appropriate treatment, 5-year survival rates range from 70-90%, depending on patient age, disease severity, and treatment response. Stem cell transplantation offers the highest cure rates, with long-term survival exceeding 90% in young patients with matched sibling donors. Immunosuppressive therapy achieves response rates of 60-80%, though some patients may relapse or develop clonal evolution. Age is a significant prognostic factor, with younger patients generally having better outcomes. Severity at diagnosis, measured by absolute neutrophil count and platelet count, also influences prognosis. Patients achieving complete response to treatment can expect near-normal life expectancy and quality of life, while those with partial response may require ongoing monitoring and supportive care.

Quality of life

Living with aplastic anemia requires careful attention to infection prevention and bleeding precautions. Patients should maintain good hygiene, avoid crowded places during periods of low white blood cell counts, and seek prompt medical attention for signs of infection. A balanced diet rich in iron and vitamins supports overall health, though iron supplements should be used cautiously due to transfusion-related iron accumulation. Regular, moderate exercise is beneficial but contact sports should be avoided when platelet counts are low. Mental health support is crucial, as the diagnosis and treatment can be emotionally challenging. Many patients benefit from counseling and support groups. Work and school accommodations may be necessary during treatment, but many patients can return to normal activities after achieving remission. Building a strong support network and maintaining open communication with healthcare teams enhances overall wellbeing.

Pregnancy and fertility

Aplastic anemia can affect fertility and pregnancy outcomes. The condition itself may cause menstrual irregularities, and some treatments, particularly stem cell transplantation conditioning regimens, can impact fertility. Women planning pregnancy should work closely with hematologists and high-risk obstetricians. Immunosuppressive medications may need adjustment during pregnancy, as some pose teratogenic risks. Ciclosporin is generally considered safer during pregnancy than other immunosuppressives. Pregnancy in women with aplastic anemia requires careful monitoring of blood counts and may necessitate increased transfusion support. For inherited forms, genetic counseling is essential to discuss transmission risks to offspring. Fertility preservation options should be discussed before starting potentially sterilizing treatments, particularly in younger patients.

Children

Pediatric aplastic anemia often has different characteristics from adult disease, with a higher likelihood of inherited bone marrow failure syndromes. Children typically respond better to treatment but require specialized pediatric hematology care. Growth and development must be monitored carefully, as both the disease and treatments can affect normal development. Educational accommodations may be necessary during treatment periods. Family support is crucial, and child life specialists can help children cope with hospitalization and procedures. Long-term follow-up is essential to monitor for late effects of treatment, including growth delays, endocrine dysfunction, and secondary malignancies. Vaccination schedules may need modification, with live vaccines contraindicated during immunosuppressive treatment.

When to see a doctor

Seek immediate medical attention for signs of severe infection including fever over 100.4°F (38°C), chills, severe fatigue, or any sign of serious infection. Emergency care is needed for severe bleeding that doesn’t stop with pressure, blood in urine or stool, severe headaches, or difficulty breathing. Routine follow-up is essential for monitoring blood counts, adjusting medications, and screening for complications. Patients should contact their healthcare team for new bruising, increased fatigue, signs of infection, or any concerning symptoms. Regular monitoring appointments are crucial even when feeling well, as blood counts can change rapidly. Dental work or surgery requires coordination with the hematology team to ensure safe platelet levels and infection prevention measures.

Regional context

Limited specific data exists for aplastic anemia prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. The global incidence of 2 per million annually likely applies to these regions, though environmental factors, genetic background, and healthcare access may influence local patterns. Some studies suggest slightly higher rates in certain Asian populations, possibly due to genetic factors or environmental exposures. Regional medical centers increasingly participate in international treatment protocols and clinical trials. Healthcare infrastructure improvements in these regions have enhanced diagnostic capabilities and treatment access. The Georgian Medical Journal welcomes contributions from regional hematologists and researchers to better understand aplastic anemia patterns and outcomes in the Caucasus and Eastern Mediterranean regions.

Research and clinical trials

Current research focuses on improving treatment outcomes and reducing long-term complications. Promising areas include novel immunosuppressive approaches, combination therapies with thrombopoietin receptor agonists, and improved stem cell transplantation techniques including haploidentical transplants. Gene therapy approaches are being investigated for inherited forms. Research on biomarkers to predict treatment response and identify patients at risk for clonal evolution continues. Clinical trials are evaluating new drugs, improved supportive care measures, and strategies to prevent graft-versus-host disease in transplant patients. The ClinicalTrials.gov database lists current studies, and patients may benefit from discussing trial participation with their healthcare teams. International collaborative research efforts are improving understanding of pathophysiology and developing personalized treatment approaches.

Frequently asked questions

Is aplastic anemia a type of cancer?

No, aplastic anemia is not cancer. It’s a bone marrow failure syndrome where the bone marrow doesn’t produce enough blood cells, but it doesn’t involve malignant cell growth like cancer does.

Can aplastic anemia be cured?

Yes, aplastic anemia can be cured, particularly with stem cell transplantation in appropriate candidates. Immunosuppressive therapy can also lead to long-term remission in many patients, though it may not be considered a complete cure.

Is aplastic anemia hereditary?

Aplastic anemia can be either acquired (most common, about 80-90% of cases) or inherited. Inherited forms are caused by genetic mutations, while acquired forms typically result from autoimmune processes.

How long does treatment take?

Treatment duration varies significantly. Immunosuppressive therapy typically requires several months to show response, with ongoing treatment often needed for years. Stem cell transplantation requires intensive initial treatment followed by long-term monitoring.

Can people with aplastic anemia live normal lives?

Many people with successfully treated aplastic anemia can return to normal or near-normal lives, including work, school, and family activities. However, ongoing medical monitoring and some lifestyle modifications may be necessary.

Support and resources

Aplastic Anemia & MDS International Foundation: www.aamds.org – Comprehensive patient support, education, and advocacy
National Organization for Rare Disorders (NORD): rarediseases.org – Rare disease information and support
Orphanet: orpha.net – European database of rare diseases
EURORDIS: eurordis.org – European rare disease advocacy
Be The Match: bethematch.org – Bone marrow donor registry and patient support
World Health Organization: who.int – Global health information and guidelines

Related conditions

Myelodysplastic syndrome
Fanconi anemia
Paroxysmal nocturnal hemoglobinuria
Acute leukemia
Diamond-Blackfan anemia

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.